ST. LOUIS, Oct. 5 /PRNewswire/ -- ISTO Technologies, Inc. (ISTO), an orthobiologics company with a cell-based platform for cartilage regeneration, announced today the completion of patient enrollment in the Phase I clinical study for NuQu™, an injectable formulation of juvenile chondrocytes designed for the treatment of discogenic back pain. The study included 15 patients enrolled at two clinical sites. All patients enrolled in the trial suffered from persistent discogenic back pain and disability despite undergoing previous traditional conservative therapy.
NuQu, a cell-based therapy derived from ISTO's platform technology for cartilage regeneration, is intended as an early intervention treatment for patients suffering from low back pain by potentially repairing, regenerating and restoring function to the disc. In preclinical studies, the juvenile chondrocytes used in the NuQu program have shown to have far greater regenerative potential than adult cartilage cells in both in vitro and in vivo environments.
"ISTO is excited about the completion of this clinical milestone that brings the promise of our novel spine therapy for patients suffering from chronic back pain one step closer to commercialization. The completion of patient enrollment for the Phase I trial is a major achievement for ISTO and our novel NuQu cell-based disc regeneration program. We look forward to analyzing the six-month interim results from the trial in early 2011 and moving NuQu to the next stage of clinical development," said Mitchell Seyedin, PhD, President and CEO of ISTO Technologies. "We wish to thank our investigators and their dedicated teams for their continued support of this innovative cell-based technology," continued Dr. Seyedin.
The principal investigators in this pilot study are Dr. Domagoj Coric of Carolina Neurosurgery and Spine Associates, Chief, Department of Neurosurgery, Caroli
|SOURCE ISTO Technologies, Inc.|
Copyright©2010 PR Newswire.
All rights reserved